Table 3.
RSV‐associated clinical outcomes in the JMDC population
| 2017 | 2018 | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Age (months) | All (0–23) | 0–2 | 3–5 | 6–11 | 12–23 | All (0–23) | 0–2 | 3–5 | 6–11 | 12–23 |
| RSV hospitalization (%) | 2,473 (100.0) | 518 (20.9) | 447 (18.1) | 565 (22.8) | 943 (38.1) | 2,083 (100.0) | 488 (23.4) | 395 (19.0) | 453 (21.7) | 747 (35.9) |
| ICU admissions (%) | 3 (0.1) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 2 (0.2) | 1 (0.0) | 1 (0.2) | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| Ventilator use (%) | 164 (6.6) | 46 (8.9) | 40 (8.9) | 52 (9.2) | 26 (2.8) | 168 (8.1) | 39 (8.0) | 45 (11.4) | 60 (13.2) | 24 (3.2) |
| RSV mortality | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
ICU: intensive care unit; JMDC: Japan Medical Data Center; RSV: respiratory syncytial virus.